331 related articles for article (PubMed ID: 21753157)
1. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
[TBL] [Abstract][Full Text] [Related]
2. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
Secchiero P; Voltan R; di Iasio MG; Melloni E; Tiribelli M; Zauli G
Clin Cancer Res; 2010 Mar; 16(6):1824-33. PubMed ID: 20215548
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
[TBL] [Abstract][Full Text] [Related]
4. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
[TBL] [Abstract][Full Text] [Related]
6. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.
Zauli G; di Iasio MG; Secchiero P; Dal Bo M; Marconi D; Bomben R; Del Poeta G; Gattei V
Curr Cancer Drug Targets; 2009 Jun; 9(4):510-8. PubMed ID: 19519319
[TBL] [Abstract][Full Text] [Related]
7. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
[TBL] [Abstract][Full Text] [Related]
8. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.
Agnoletto C; Melloni E; Casciano F; Rigolin GM; Rimondi E; Celeghini C; Brunelli L; Cuneo A; Secchiero P; Zauli G
Oncotarget; 2014 Jun; 5(12):4347-60. PubMed ID: 24962518
[TBL] [Abstract][Full Text] [Related]
9. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
10. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.
Zauli G; Voltan R; di Iasio MG; Bosco R; Melloni E; Sana ME; Secchiero P
Clin Cancer Res; 2011 May; 17(9):2712-24. PubMed ID: 21367750
[TBL] [Abstract][Full Text] [Related]
11. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
12. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
[TBL] [Abstract][Full Text] [Related]
13. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.
di Iasio MG; Norcio A; Melloni E; Zauli G
Invest New Drugs; 2012 Dec; 30(6):2403-6. PubMed ID: 22238073
[TBL] [Abstract][Full Text] [Related]
14. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
15. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P
J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964
[TBL] [Abstract][Full Text] [Related]
16. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
Voltan R; Secchiero P; Corallini F; Zauli G
Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
18. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
19. Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.
Secchiero P; Rimondi E; di Iasio MG; Voltan R; Gonelli A; Zauli G
J Cell Physiol; 2012 May; 227(5):1829-37. PubMed ID: 21732354
[TBL] [Abstract][Full Text] [Related]
20. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).
Secchiero P; Barbarotto E; Tiribelli M; Zerbinati C; di Iasio MG; Gonelli A; Cavazzini F; Campioni D; Fanin R; Cuneo A; Zauli G
Blood; 2006 May; 107(10):4122-9. PubMed ID: 16439677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
